Corriente Advisors, LLC Oncorus, Inc. Transaction History

Corriente Advisors, LLC

  • $9.53 Million
  • Q4 2023

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 18, 2021
SELL
$11.89 - $35.55 $927,931 - $2.77 Million
-78,043 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$15.0 - $35.15 $1.17 Million - $2.74 Million
78,043 New
78,043 $2.52 Million

About Oncorus, Inc.

ONCR Quotes by TradingView
  • Ticker ONCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,973,100
  • Description
  • Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...
More about ONCR
Track This Portfolio

Track Corriente Advisors, LLC Portfolio

Follow Corriente Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corriente Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Corriente Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email